115 related articles for article (PubMed ID: 36729959)
1. The fibroblast growth factor receptor inhibitor, derazantinib, has strong efficacy in human gastric tumor models and synergizes with paclitaxel in vivo.
McSheehy PMJ; Forster-Gross N; El Shemerly M; Bachmann F; Roceri M; Hermann N; Spickermann J; Kellenberger L; Lane HA
Anticancer Drugs; 2023 Apr; 34(4):532-543. PubMed ID: 36729959
[TBL] [Abstract][Full Text] [Related]
2. Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models.
El Shemerly M; Zanini E; Lecoultre M; Walker PR; Kellenberger L; Lane HA; McSheehy PMJ
Anticancer Drugs; 2023 Oct; 34(9):1035-1045. PubMed ID: 36729099
[TBL] [Abstract][Full Text] [Related]
3. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
4. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
[TBL] [Abstract][Full Text] [Related]
6. FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy.
Quintanal-Villalonga A; Molina-Pinelo S; Cirauqui C; Ojeda-Márquez L; Marrugal Á; Suarez R; Conde E; Ponce-Aix S; Enguita AB; Carnero A; Ferrer I; Paz-Ares L
J Thorac Oncol; 2019 Apr; 14(4):641-655. PubMed ID: 30639621
[TBL] [Abstract][Full Text] [Related]
7. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
Liu PCC; Koblish H; Wu L; Bowman K; Diamond S; DiMatteo D; Zhang Y; Hansbury M; Rupar M; Wen X; Collier P; Feldman P; Klabe R; Burke KA; Soloviev M; Gardiner C; He X; Volgina A; Covington M; Ruggeri B; Wynn R; Burn TC; Scherle P; Yeleswaram S; Yao W; Huber R; Hollis G
PLoS One; 2020; 15(4):e0231877. PubMed ID: 32315352
[TBL] [Abstract][Full Text] [Related]
8. DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo.
Dai MD; Wang YL; Fan J; Dai Y; Ji YC; Sun YM; Peng X; Li LL; Wang YM; Duan WH; Ding J; Ai J
Acta Pharmacol Sin; 2021 Sep; 42(9):1498-1506. PubMed ID: 33288861
[TBL] [Abstract][Full Text] [Related]
9. Probing the Effects of the FGFR-Inhibitor Derazantinib on Vascular Development in Zebrafish Embryos.
Kotini MP; Bachmann F; Spickermann J; McSheehy PM; Affolter M
Pharmaceuticals (Basel); 2020 Dec; 14(1):. PubMed ID: 33396726
[TBL] [Abstract][Full Text] [Related]
10. BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.
Kim SH; Ryu H; Ock CY; Suh KJ; Lee JY; Kim JW; Lee JO; Kim JW; Kim YJ; Lee KW; Bang SM; Kim JH; Lee JS; Ahn JB; Kim KJ; Rha SY
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30326563
[TBL] [Abstract][Full Text] [Related]
11. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
[TBL] [Abstract][Full Text] [Related]
12. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
[TBL] [Abstract][Full Text] [Related]
13. Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma.
Raggi C; Fiaccadori K; Pastore M; Correnti M; Piombanti B; Forti E; Navari N; Abbadessa G; Hall T; Destro A; Di Tommaso L; Roncalli M; Meng F; Glaser S; Rovida E; Peraldo-Neia C; Olaizola P; Banales JM; Gerussi A; Elvevi A; Droz Dit Busset M; Bhoori S; Mazzaferro V; Alpini G; Marra F; Invernizzi P
Am J Pathol; 2019 Oct; 189(10):2090-2101. PubMed ID: 31351075
[TBL] [Abstract][Full Text] [Related]
14. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.
Guagnano V; Kauffmann A; Wöhrle S; Stamm C; Ito M; Barys L; Pornon A; Yao Y; Li F; Zhang Y; Chen Z; Wilson CJ; Bordas V; Le Douget M; Gaither LA; Borawski J; Monahan JE; Venkatesan K; Brümmendorf T; Thomas DM; Garcia-Echeverria C; Hofmann F; Sellers WR; Graus-Porta D
Cancer Discov; 2012 Dec; 2(12):1118-33. PubMed ID: 23002168
[TBL] [Abstract][Full Text] [Related]
15. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
16. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
17. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
[TBL] [Abstract][Full Text] [Related]
18. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
[TBL] [Abstract][Full Text] [Related]
20. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
